Quercetin and naringenin transport across human intestinal Caco-2 cells

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 11, 2009, Pages 1473-1483

  Chabane, Meriem Nait ^a   Al Ahmad, Abraham ^a   Peluso, Jean ^a   Muller, Christian D ^a   Ubeaud, Genevieve ^a,b  

^a Faculté de Pharmacie   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Absorption; Caco 2 cell; Flavonoids; Naringenin; Quercetin; Transporter

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLYCOPROTEIN P; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NARINGENIN; ORGANIC ANION TRANSPORTING PROTEIN B; QUERCETIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; PH; POLARIZATION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS;

EID: 75749097381     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.11.0006     Document Type: Article

References (49)

1. Kühnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 1976; 24: 177-191.
2. St Leger AS et al. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet 1979; 1: 1017-1020.
3. Middleton E, Kandaswami C. The Flavonoids: Advances in Research since 1986. Harborne, JB, ed. London: Chapman & Hall, 1993: 619-652.
4. Kandaswami C, Middleton E Jr. Free radical scavenging and antioxidant activity of plant flavonoids. Adv Exp Med Biol 1994; 366: 351-376.
5. Martin S et al. Delphinidin inhibits endothelial cell proliferation and cell cycle progression through a transient activation of ERK-1/-2. Biochem Pharmacol 2003; 65: 669-675.
6. Martin S et al. Delphinidin, an active compound of red wine, inhibits endothelial cell apoptosis via nitric oxide pathway and regulation of calcium homeostasis. Br J Pharmacol 2003; 139: 1095-1102.
7. Hollman PCH, Katan MB. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 1999; 37: 937-942.
8. Schwenk M. Drug transport in intestine liver and kidney. Arch Toxicol 1987; 60: 37-42.
9. Custodio JM et al. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008; 60: 717-733.
10. Walgren RA et al. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol 1998; 55: 1721-1727.
11. Olthof MR et al. Bioavailabilities of quercetin-3-glucoside and quercetin-4′-glucoside do not differ in humans. J Nutr 2000; 130: 1200-1203.
12. Hollmann PCH et al. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62: 1276-1282.
13. Kottra G, Daniel H. Flavonoid glycosides are not transported by the human Na+/glucose transporter when expressed in Xenopus laevis oocytes, but effectively inhibit electrogenic glucose uptake. J Pharmacol Exp Ther 2007; 322: 829-835.
14. Walle T, Walle UK. The β-D-glucoside and sodium dependent glucose transporter 1 (SGLT1)-inhibitor phloridzin is transported by both SGLT1 and multidrug resistance associated proteins 1/2. Drug Metab Dispos 2003; 31: 1288-1291.
15. Walgren RA et al. Cellular uptake of dietary flavonoid quercetin 4′ beta glucoside by sodium dependent glucose transporter SGLT1. J Pharmacol Exp Ther 2000; 294: 837-843.
16. Cermak R et al. Quercetin glucosides inhibit glucose uptake into brush-border membrane vesicles of porcine jejunum. Br J Nutr 2004; 91: 849-855.
17. DiPietro A et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 2002; 59: 307-322.
18. Conseil G et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998; 95: 9831-9836.
19. Takanaga H et al. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol Pharm Bull 1998; 21: 1062-1066.
20. Bailey DG et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-110.
21. Ubeaud G, Le Goff-Klein N. Interaction between the simvastatin, a HMG CoA reductase inhibitor, and the grapefruit juice: In vitro characterization and in vivo relevance. In: Recent Research Developments in Life Science, Pandalai SG, ed. Trivandrum, India: Research Signpost, 2005; 3: 337-352.
22. Le Goff N et al. Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin. Eur J Drug Metab Pharmacokinet 2002; 27: 233-241.
23. Lush RM et al. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 1997; 37: 123-128.
24. Summers MA. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004; 38: 1631-1634.
25. Mallants R et al. Multidrug resistance-associated protein 2(MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005; 35: 1055-1066.
26. Wu C et al. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4), that are present in human red cell membranes. Biochem Pharmacol 2005; 70: 500-510.
27. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003; 33: 1-5.
28. Smith JG et al. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vacc Immunol 2007: 527-537.
29. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
30. Petri N et al. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 2004; 21: 1398-1404.
31. Mandagere K et al. Graphical model for estimating oral bioavailability of drug in humans and others species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 2002; 45: 304-311.
32. Artursson P. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco2) cells. J Pharm Sci 1990; 79: 476-482.
33. Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000; 60: 1381-1390.
34. Nozawa T et al. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308: 438-445.
35. Troutman MD, Thakker DR. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 2003; 20: 1210-1224.
36. Van Dijk C et al. The uncoupling efficiency and affinity of flavonoids for vesicles. Biochem Pharmacol 2000; 60: 1593-1600.
37. Neuhoff S et al. pH dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Pharm Sci 2005; 25: 211-220.
38. Rodriguez-Proteau R et al. Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco2 and MDCK II-MDR1 cell transport models. Xenobiotica 2006; 36: 41-58.
39. Nguyen H et al. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003; 92: 250-257.
40. Ofer M et al. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur J Pharm Sci 2005; 25: 263-271.
41. Phang JM et al. Flavonol-stimulated efflux of 7,12-dimethylbenz(a) anthracene in multidrug-resistant breast cancer cells. Cancer Res 1993; 53: 5977-5981.
42. Scambia G et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994; 34: 459-464.
43. Cermak R et al. Quercetin glucosides inhibit glucose uptake into brush-border membrane vesicles of porcine jejunum. Br J Nutr 2004; 91: 849-855.
44. Milane HA et al. Transport of quercetin di-sodium salt in the human intestinal epithelial Caco2 cell monolayer. Eur J Drug Metab Pharm 2007; 32: 139-147.
45. Mitsunaga Y et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000; 395: 193-201.
46. Zhou S et al. Herbal modulation of P glycoprotein. Drug Metab Rev 2004; 36: 57-104.
47. Vaidyanathan JB, Walle T. Cellular uptake and efflux of the tea flavonoid (-) epicatechin 3 gallate in the human intestinal cell line Caco-2. J Pharm Exp Ther 2003; 307: 745-752.
48. Casagrandre R et al. In vitro evaluation of quercetin cutaneous absorption from topical formulations and its functional stability by antioxidant activity. Int J Pharm 2007; 328: 183-190.
49. Perrissoud D, Testa B. Inhibiting or potentiating effects of flavonoids on carbon tetrachloride-induced toxicity in isolated rat hepatocytes. Arzneimittelforschung 1986; 36: 1249-1253.